Over 9 Million People Vaccinated with GSK’s RSV Vaccine

GSK's Susan Gerber, M.D., Medical Director, today confirmed that about 9 million people in the United States have been vaccinated with AREXVY, a vaccine indicated for active immunization to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV).

During the CDC's Advisory Committee on Immunization Practices meeting on October 24, 2024, Dr. Gerber reaffirmed that protecting vulnerable individuals at high risk for severe RSV disease is essential ahead of this year's RSV season.

GSK also announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for LRTD caused by RSV due to certain underlying medical conditions and in adults who are immunocompromised.

These data show the vaccine’s potential to help protect a broader group of adults at risk from the potentially serious consequences of RSV.

This U.S. FDA-approved RSV vaccine has been approved to prevent RSV-LRTD in individuals 60 years of age and older in more than 50 countries, including Europe and Japan.